Skip to main content

Table 2 Summary of results in patients on VSL#3®

From: A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

Measurements Mean pre-VSL#3® Mean post-VSL#3® p value
Systolic BP (mmHg) 133 ± 13 130 ± 11 0.53
Diastolic BP (mmHg) 82 ± 8 80 ± 7 0.42
Total cholesterol (mmol/l) 4.51 ± 1.38 4.42 ± 1.27 0.83
HDL (mmol/l) 1.07 ± 0.26 1.09 ± 0.24 0.79
LDL (mmol/l) 2.58 ± 1.18 2.56 ± 1.02 0.95
Triglycerides (mmol/l) 1.89 ± 0.57 1.91 ± 1.00 0.94
HbA1c (mmol/mol) 54 ± 12 55 ± 12 0.87
Fructosamine (μmol/l) 257 ± 44 263 ± 49 0.67
HOMA-IR 2.2 ± 1.9 2.2 ± 1.5 0.95
∆RI-GTN (%) 28 ± 6 25 ± 8 0.20
∆RI-Salb (%) 9 ± 8 8 ± 4 0.62
sVCAM-1 (ng/ml) 536 ± 305 524 ± 262 0.90
cGMP (pmol/l) 178 ± 57 159 ± 43 0.27
Blood glutathione ratio 22 ± 10 26 ± 13 0.21
TAC [mM Asc (AEAC)] 0.46 ± 0.04 0.47 ± 0.07 0.75
hsCRP (mg/l) 3.0 ± 2.5 3.9 ± 6.1 0.53
ALT (iu/l) 56 ± 31 51 ± 32 0.63
AST (iu/l) 40 ± 16 38 ± 20 0.78
Mode ASQ (C2m) 91 ± 14 95 ± 16 0.57
  1. VSL#3® treated group n = 19; placebo treated group n = 16. Data expressed as mean and standard deviation. Four cGMP values were not measurable (3 from placebo group and 1 from VSL#3® group). HOMA-IR missing 1 value from each treatment group as insulin levels were outside the HOMA calculator range. HbA1c in the placebo group had one missing value. LDL cholesterol had missing data on 1 patient from placebo group and 1 from VSL#3® group as triglycerides were > 4.5 mmol/l which preclude LDL cholesterol calculation. SBP and DBP values were missing after intervention on 1 patient in the placebo group. Nineteen patients had completed ASQ (10 in VSL#3® group and 11 in placebo group). Missing data were excluded from respective analyses